Oppenheimer reiterated an Outperform rating and $210 price target on one biotech name in a note Thursday, saying a sharp ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE